Investigational Drug Information for Ceralasertib
What is the development status for investigational drug Ceralasertib?
Ceralasertib is an investigational drug.
There have been 26 clinical trials for Ceralasertib.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 7th 2025.
The most common disease conditions in clinical trials are Neoplasms, Carcinoma, Non-Small-Cell Lung, and Lung Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Parexel.
There are one hundred and seventy-seven US patents protecting this investigational drug and ninety-three international patents.
Summary for Ceralasertib
| US Patents | 177 |
| International Patents | 93 |
| US Patent Applications | 474 |
| WIPO Patent Applications | 336 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 1 (2025-08-07) |
| Vendors | 28 |
Recent Clinical Trials for Ceralasertib
| Title | Sponsor | Phase |
|---|---|---|
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study | National Cancer Institute (NCI) | PHASE2 |
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study | SWOG Cancer Research Network | PHASE2 |
| Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer | National Cancer Institute (NCI) | PHASE3 |
Clinical Trial Summary for Ceralasertib
Top disease conditions for Ceralasertib
Top clinical trial sponsors for Ceralasertib
US Patents for Ceralasertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ceralasertib | ⤷ Start Trial | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Start Trial |
| Ceralasertib | ⤷ Start Trial | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | Chempartner Corp , University of Texas System | ⤷ Start Trial |
| Ceralasertib | ⤷ Start Trial | Heterocyclic inhibitors of ATR kinase | Board of Regents, The University of Texas System (Austin, TX) ChemPartner Corporation (South San Francisco, CA) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ceralasertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ceralasertib | Argentina | AR107001 | 2035-12-17 | ⤷ Start Trial |
| Ceralasertib | Australia | AU2016370916 | 2035-12-17 | ⤷ Start Trial |
| Ceralasertib | Brazil | BR112017002594 | 2035-12-17 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
Ceralasertib Development Update, Patent Position, Clinical Pipeline, and Market Projection
Ceralasertib, also known as AZD6738, is AstraZeneca’s oral, selective ATR inhibitor in clinical development for biomarker-defined solid tumors. It has no FDA approval, no established commercial launch date, and no Orange Book listing. Its value depends on demonstrating that ATR inhibition produces clinically meaningful benefit in tumors with replication stress or defects in DNA-damage-response pathways, including ATM loss, ARID1A loss, and selected BRCA or homologous-recombination-deficient tumors.
The commercial outlook is conditional. Ceralasertib could support a specialty oncology product with peak annual sales in the low hundreds of millions of dollars if AstraZeneca secures a biomarker-selected indication. A broad, unselected solid-tumor label appears unlikely based on the mixed results of combination and monotherapy programs.
What is the current development status of ceralasertib?
Ceralasertib remains an investigational ATR inhibitor. AstraZeneca has evaluated it as monotherapy and in combinations with durvalumab, olaparib, chemotherapy, and other anticancer agents.
| Attribute | Current status |
|---|---|
| International nonproprietary name | Ceralasertib |
| Development code | AZD6738 |
| Developer | AstraZeneca |
| Drug class | Oral, selective ATR kinase inhibitor |
| Primary mechanism | Blocks ATR-mediated replication-stress response and DNA-damage signaling |
| FDA approval | None |
| FDA breakthrough designation | No publicly established approval |
| Orange Book listing | None |
| Commercial launch | No launch announced |
| Principal development strategy | Biomarker-selected solid tumors and combination therapy |
| Key biomarkers | ATM loss, ARID1A loss, replication stress, homologous-recombination deficiency |
| Main competitors | Camonsertib, elimusertib, berzosertib, tuvusertib |
ATR inhibition is designed to exploit tumors that already have impaired DNA-damage repair. ATR inhibition can increase replication catastrophe and tumor-cell death, but it also creates dose-limiting hematologic toxicity, particularly thrombocytopenia, anemia, and neutropenia. This toxicity has complicated combination development with platinum chemotherapy, PARP inhibitors, and other DNA-damaging agents.
Which clinical trials are evaluating ceralasertib?
Ceralasertib has been studied across several clinical settings, with the strongest development rationale in biomarker-enriched disease.
Ceralasertib monotherapy
Early-phase studies established proof of mechanism and identified activity in selected tumors, including cancers with ATM deficiency and other defects in DNA-damage response. Monotherapy activity has generally been modest in unselected populations. The development case therefore depends on improving patient selection rather than pursuing a broad solid-tumor indication.
AstraZeneca’s early trials included dose-escalation and expansion cohorts in advanced solid tumors. These studies examined pharmacokinetics, recommended dosing, safety, and preliminary response rates. The program identified intermittent dosing as important for managing hematologic toxicity.
Ceralasertib plus durvalumab
The combination with durvalumab, AstraZeneca’s anti-PD-L1 antibody, was evaluated because ATR inhibition can increase DNA damage, inflammatory signaling, and tumor immunogenicity.
The HUDSON study evaluated durvalumab-based combinations in patients with previously treated non-small-cell lung cancer, including ceralasertib-containing cohorts. ClinicalTrials.gov identifies HUDSON as NCT03334640. The study explored biomarker-defined populations and multiple targeted combinations rather than testing ceralasertib as a standalone product.
The rationale was strongest in tumors with DNA-repair defects. The key commercial issue is whether ceralasertib adds sufficient benefit to durvalumab to justify a new combination regimen after progression on standard immunotherapy and chemotherapy.
Ceralasertib plus olaparib
The ceralasertib-olaparib combination has been tested in advanced cancers with homologous-recombination or replication-stress features. The approach seeks to create synthetic lethality by simultaneously disrupting ATR-mediated replication control and PARP-dependent DNA repair.
The principal development risks are overlapping marrow toxicity, dose interruptions, and competition from established PARP inhibitors. A label based on ATM loss or another sharply defined molecular alteration would improve the development logic, but it would also reduce the addressable population.
Ceralasertib plus chemotherapy
Ceralasertib has been studied with platinum agents, paclitaxel, gemcitabine, and other cytotoxic regimens. These combinations have biological rationale but present the most difficult safety profile. Dose intensity can fall when the ATR inhibitor is combined with chemotherapy, reducing efficacy even if the mechanism is active.
The TACTIC-E program evaluated ceralasertib with chemotherapy in advanced triple-negative breast cancer. The program did not establish a broadly practice-changing benefit in an unselected population. This result weakens the case for a large breast-cancer label but does not eliminate the possibility of a biomarker-defined indication.
Ceralasertib in ARID1A-deficient tumors
ARID1A loss is another proposed sensitivity marker. The ATARI trial evaluated ceralasertib in gynecologic cancers with ARID1A deficiency or related molecular features. The study is important because it tests whether a defined synthetic-lethal relationship can translate into clinical activity.
The central question is whether ARID1A loss alone is sufficiently predictive. If the biomarker has low positive predictive value, AstraZeneca may need a composite diagnostic approach incorporating ARID1A status, replication stress, ATM function, and genomic instability.
What is the FDA regulatory status of ceralasertib?
Ceralasertib has no FDA-approved indication and no publicly established FDA filing or approval date. It is not an FDA-approved active ingredient, and no ceralasertib product appears in the FDA Orange Book as an approved drug product.
| Regulatory question | Answer |
|---|---|
| Has FDA approved ceralasertib? | No |
| Is ceralasertib in the Orange Book? | No approved listing identified |
| Is there an approved generic? | No |
| Is there an FDA reference listed drug? | No |
| Has FDA assigned a product exclusivity period? | No |
| Is a biosimilar pathway relevant? | No; ceralasertib is a small molecule |
| Most likely future filing route | New Drug Application under Section 505(b)(1) |
If approved, ceralasertib would likely receive a narrow oncology label tied to a molecularly defined population. A companion diagnostic could be required or strongly encouraged if the approval rests on ATM, ARID1A, or another tumor-genomic marker.
What patents protect ceralasertib?
Ceralasertib is protected primarily through small-molecule patent families covering the active compound, related chemical classes, pharmaceutical compositions, and therapeutic uses. The original composition-of-matter protection is more commercially important than later method-of-use patents because the compound has not yet established an approved indication.
| Patent category | Commercial role |
|---|---|
| Composition-of-matter patents | Core protection for ceralasertib and related ATR-inhibitor structures |
| Crystalline or salt-form patents | May protect solid-state properties, stability, or manufacturing advantages |
| Formulation patents | May protect oral dosage forms, excipients, release profiles, or administration schedules |
| Method-of-use patents | May cover ATM-deficient, ARID1A-deficient, BRCA-mutant, or other biomarker-defined tumors |
| Combination patents | May cover use with durvalumab, olaparib, platinum agents, or chemotherapy |
| Manufacturing patents | May protect synthetic routes, intermediates, purification, or scale-up processes |
Public compound naming and patent records associate AZD6738 with AstraZeneca’s ATR-inhibitor research program. The exact remaining term depends on the jurisdiction, patent family, prosecution history, terminal disclaimers, patent-term adjustment, and any patent-term extension obtained after approval.
No ceralasertib patent-term extension or pediatric exclusivity period is publicly established because the product has not been approved. The absence of an Orange Book listing also means there is no current FDA patent-certification framework for generic applicants.
When could ceralasertib lose exclusivity?
Ceralasertib has not entered the market, so its commercial exclusivity clock has not started. If AstraZeneca obtains approval, the relevant protections would include:
- Patent exclusivity, primarily from composition-of-matter claims.
- Five-year new chemical entity exclusivity, if FDA determines that ceralasertib is an eligible new chemical entity.
- Three-year approval exclusivity for a new clinical investigation supporting a new indication or formulation.
- Seven years of orphan-drug exclusivity if an orphan indication is approved.
- Patent-term adjustment or patent-term extension, subject to statutory limits.
The likely commercial exposure is not the first generic challenge alone. A narrow label could also face off-label competition from other ATR inhibitors, PARP inhibitors, immunotherapy combinations, or alternative DNA-damage-response agents before core patent expiry.
How strong is the patent estate for ceralasertib?
The estate appears technically meaningful but commercially unproven. Core chemical patents can provide a strong barrier if they remain valid and have a substantial term at launch. Later method-of-use patents are less reliable because they may be vulnerable to written-description, enablement, obviousness, or non-infringement challenges.
Composition-of-matter protection
Composition claims generally provide the strongest exclusionary position because they cover the active molecule itself, regardless of the approved tumor type. Their value depends on:
- Remaining patent term at approval.
- Claim scope around ceralasertib and pharmaceutically acceptable forms.
- Validity after post-grant or district-court challenge.
- Ability to block alternative salts, polymorphs, and prodrugs.
- Patent-term adjustment and potential patent-term extension.
Formulation and dosing protection
Ceralasertib has been studied using intermittent dosing schedules to manage marrow toxicity. If an approved product depends on a specific schedule, formulation patents could support additional protection. These patents are usually weaker than composition patents because generic applicants may design around excipients, dosage strengths, or administration schedules.
Method-of-use protection
Potential method-of-use claims could target:
- ATM-deficient tumors.
- ARID1A-deficient tumors.
- Homologous-recombination-deficient tumors.
- Tumors resistant to PARP inhibitors.
- Combination treatment with durvalumab.
- Combination treatment with olaparib or chemotherapy.
These claims could be commercially valuable if the FDA label includes a biomarker requirement. Their litigation value would depend on whether a generic label induces use for the patented indication and whether the claims are sufficiently specific.
Are Paragraph IV challenges or generic lawsuits pending?
No Paragraph IV challenge is expected before FDA approval because ceralasertib has no Orange Book listing and no approved reference product. No public generic litigation involving ceralasertib is established in the available regulatory record.
A future ANDA challenge would require an approved reference product and Orange Book-listed patents. The likely sequence would be:
| Event | Likely timing relative to approval |
|---|---|
| NDA approval | Year 0 |
| Orange Book listing | At or shortly after approval |
| Potential Paragraph IV filing | After generic development and filing |
| 30-month litigation stay | Potentially triggered by timely patent litigation |
| First generic entry | Governed by patent outcome, settlement, and exclusivity |
A 505(b)(2) applicant could create a separate challenge route for a new formulation, dosing schedule, or combination. That route would not automatically avoid composition patents.
What companies are challenging or competing with ceralasertib?
Ceralasertib competes in the emerging ATR-inhibitor class and in the broader DNA-damage-response market.
| Company | ATR inhibitor | Development position |
|---|---|---|
| AstraZeneca | Ceralasertib | Clinical-stage program across monotherapy and combinations |
| Repare Therapeutics, with prior Roche involvement | Camonsertib, RP-3500 | Biomarker-selected ATR program, including ATM-deficient tumors |
| Bayer | Elimusertib, BAY 1895344 | Clinical development in advanced solid tumors and hematologic malignancies |
| Merck KGaA | Berzosertib, M6620 | Intravenous ATR inhibitor evaluated with chemotherapy |
| Impact Therapeutics | Tuvusertib, M1774 | Oral ATR inhibitor in early clinical development |
| Artios Pharma and collaborators | ATR-directed programs | Earlier-stage DNA-damage-response competition |
Camonsertib is the most direct competitive reference because its development strategy also emphasizes ATM-deficient and DNA-damage-response-deficient tumors. A product with a validated biomarker, durable responses, manageable cytopenias, and convenient oral dosing would have an advantage over a broader but less selective ATR program.
What is the market projection for ceralasertib?
Ceralasertib’s market opportunity is best modeled through indication scenarios rather than a single global forecast.
| Scenario | Development outcome | Addressable population | Peak annual sales estimate |
|---|---|---|---|
| Downside | Program discontinued or no registrational efficacy | None | $0 |
| Narrow approval | One biomarker-defined refractory indication | 5,000-15,000 treated patients globally | $75 million-$250 million |
| Base case | One or two biomarker-defined solid-tumor indications | 15,000-35,000 patients | $250 million-$600 million |
| Upside | Multiple combinations and earlier-line use | 35,000-70,000 patients | $600 million-$1.2 billion |
These figures are analyst scenario estimates, not reported company guidance. They assume annual net pricing of approximately $50,000-$100,000, regional access restrictions, and substantial competition from other targeted oncology products.
The most credible commercial path is a specialty product for patients with a defined DNA-repair defect after standard therapy. The least credible path is a broad monotherapy launch across all advanced solid tumors.
Revenue exposure for AstraZeneca
Ceralasertib is not currently a material revenue contributor because it has no product sales. Its financial importance is strategic rather than current. AstraZeneca would need positive randomized data to justify the cost of companion-diagnostic development, registrational trials, manufacturing scale-up, and commercial infrastructure.
The product could have value as part of AstraZeneca’s broader oncology portfolio, particularly alongside durvalumab and olaparib. A successful combination label could protect franchise economics but might also create internal cannibalization if ceralasertib is used after progression on other AstraZeneca medicines.
What manufacturing and intellectual-property barriers affect ceralasertib?
Ceralasertib is an oral small molecule, so manufacturing barriers are lower than for biologics. The principal barriers are chemical-process control, impurity management, polymorph control, and scale-up of the final active pharmaceutical ingredient.
Key manufacturing risks include:
- Reproducible synthesis at commercial scale.
- Control of chiral or regioisomeric impurities, if applicable to the final route.
- Stable solid-state form and tablet performance.
- Consistent exposure under intermittent dosing.
- Supply-chain qualification for active ingredient and specialized intermediates.
Because ceralasertib is a small molecule, biosimilar risk is irrelevant. Generic competition would be the relevant post-exclusivity threat. The strongest protection would come from a valid composition patent combined with a label-linked method-of-use patent.
What litigation or settlement agreements affect ceralasertib?
No major public patent litigation, Paragraph IV settlement, or generic-entry agreement involving ceralasertib is established. The litigation profile will remain limited until AstraZeneca obtains an approved product and lists enforceable patents in the Orange Book.
Potential future disputes would likely involve:
- Validity of core composition claims.
- Infringement by alternative salts or polymorphs.
- Induced infringement of biomarker-specific treatment methods.
- Patent-term extension calculations.
- Combination patents covering ceralasertib with durvalumab or olaparib.
- 505(b)(2) applications directed to formulations or dosing schedules.
How does ceralasertib compare with other ATR inhibitors?
Ceralasertib has a competitive advantage in AstraZeneca’s oncology infrastructure and in its clinical combination history with durvalumab and olaparib. Its disadvantages are the lack of an approved indication, uncertain late-stage efficacy, and the class-wide problem of hematologic toxicity.
| Factor | Ceralasertib | Camonsertib | Elimusertib |
|---|---|---|---|
| Route | Oral | Oral | Oral |
| Developer scale | Large pharmaceutical company | Biotechnology-led program | Large pharmaceutical company |
| Biomarker strategy | ATM, ARID1A, replication stress, HRD | Strong focus on ATM and DDR defects | Molecularly selected solid tumors |
| Combination depth | Immunotherapy, PARP inhibition, chemotherapy | DDR-focused combinations | Chemotherapy and targeted combinations |
| Commercial readiness | Pre-approval | Pre-approval | Pre-approval |
| Main risk | Failure to convert biomarker rationale into registrational efficacy | Narrow population and toxicity | Dose intensity and class competition |
Key Takeaways
- Ceralasertib is an investigational oral ATR inhibitor developed by AstraZeneca.
- It has no FDA approval, Orange Book listing, approved generic, or established commercial launch date.
- The strongest development rationale is in biomarker-defined tumors with ATM loss, ARID1A loss, homologous-recombination deficiency, or high replication stress.
- Broad use in unselected solid tumors appears unlikely.
- No Paragraph IV challenge, generic litigation, or public settlement agreement is established.
- Composition-of-matter patents are likely to provide the strongest protection; formulation and method-of-use patents may extend commercial coverage but are more vulnerable.
- A realistic peak-sales range is $250 million-$600 million if AstraZeneca secures one or two biomarker-selected indications.
- The principal value inflection point is registrational evidence showing that biomarker selection produces durable clinical benefit without unacceptable marrow toxicity.
FAQs About Ceralasertib
Is ceralasertib approved for cancer treatment?
No. Ceralasertib has not received FDA approval or an established marketing authorization from a major regulatory agency.
Is ceralasertib a PARP inhibitor?
No. Ceralasertib is an ATR inhibitor. It is being evaluated with PARP inhibitors such as olaparib because combined blockade may increase tumor-cell DNA damage.
What cancers may respond to ceralasertib?
Potentially responsive cancers include tumors with ATM loss, ARID1A loss, homologous-recombination deficiency, or other replication-stress phenotypes. The predictive value of each biomarker remains under clinical evaluation.
Will ceralasertib have a biosimilar competitor?
No. Ceralasertib is a small-molecule drug, so post-exclusivity competition would come through generic or 505(b)(2) applications rather than biosimilars.
What is the main investment risk for ceralasertib?
The main risk is failure to demonstrate that a molecular biomarker can identify patients with a sufficiently high response rate and durable benefit to support regulatory approval and commercial adoption.
References
-
AstraZeneca. (2024). Annual report and form 20-F 2023. AstraZeneca PLC.
-
ClinicalTrials.gov. (n.d.). A study of durvalumab combinations in patients with advanced non-small cell lung cancer: HUDSON, NCT03334640. U.S. National Library of Medicine.
-
ClinicalTrials.gov. (n.d.). A study of ceralasertib in patients with advanced solid tumors. U.S. National Library of Medicine.
-
ClinicalTrials.gov. (n.d.). ATARI: Ceralasertib in patients with ARID1A-deficient gynecological cancers, NCT04065269. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
Yap, T. A., O’Carrigan, B., Penney, M. S., et al. (2021). Phase I study of the ATR inhibitor ceralasertib in combination with chemotherapy and other anticancer agents. Journal of Clinical Oncology, 39(27), 2957-2968.
-
Foote, K. M., Lau, A., & Nissink, J. W. M. (2015). Drugging the anti-cancer DNA damage response in the clinic. Nature Reviews Cancer, 15(10), 599-614.
More… ↓
